Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus VERSAPEN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus VERSAPEN K.
LAROTID vs VERSAPEN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
VERSAPEN-K (hetacillin potassium) is a prodrug that is hydrolyzed to ampicillin, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
250-500 mg intramuscularly or intravenously every 6 hours for moderate infections; 1-2 g every 6 hours for severe infections.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.8-1.5 hours in adults with normal renal function (prolonged to 6-20 hours in severe renal impairment; dosing adjustment required when CrCl <30 mL/min).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: 15-20% as active drug; fecal: <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic